Streetbeat News

Analyst Ratings

BLCO

Needham analyst David Saxon has reiterated a Hold rating on Bausch & Lomb (NYSE:BLCO).

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:01 am

SUI

Evercore ISI Group has downgraded Sun Communities from Outperform to In-Line, while raising the price target from $144 to $149.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:59 am

TTGT

Needham analyst Joshua Reilly maintains a Buy rating on TechTarget (NASDAQ:TTGT) but lowers the price target from $50 to $40.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:58 am

CHCT

Evercore ISI Group has upgraded Community Healthcare (NYSE:CHCT) from Underperform to In-Line, while lowering the price target from $21 to $18.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:57 am

SLG

Evercore ISI Group has upgraded SL Green Realty (NYSE:SLG) from Underperform to In-Line and increased the price target from $55 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:54 am

REPL

HC Wainwright & Co. has reiterated its Buy rating for Replimune Group, maintaining a price target of $17. Analyst Robert Burns continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:53 am

EGP

Evercore ISI Group has upgraded EastGroup Properties (NYSE:EGP) from In-Line to Outperform, raising the price target from $192 to $204.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:51 am

SMMT

HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics and raised the price target from $30 to $45, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:51 am

SPG

Evercore ISI Group has upgraded Simon Property Group (NYSE:SPG) from In-Line to Outperform, raising the price target from $160 to $172.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:49 am

HALO

HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, maintaining a price target of $65. Analyst Mitchell Kapoor continues to see potential in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:49 am